Esperion Presents New Data on Cholesterol-Lowering Drugs at European Atherosclerosis Society Congress

Esperion Therapeutics presented new clinical data regarding its treatments for lowering cardiovascular risk factors like LDL cholesterol at the European Atherosclerosis Society (EAS) annual congress in Athens, Greece, in late May 2026.

The congress featured results from a Phase 2 study evaluating bempedoid acid in children aged 6-17 years with heterozygous familial hypercholesterolemia. The study indicated that bempedoid acid reduced LDL cholesterol in these pediatric patients by 6–25% and was well-tolerated without raising new safety concerns. These findings support the dosage levels for bempedoid acid in upcoming Phase 3 studies.

Additionally, a post hoc analysis from the CLEAR Outcomes trial was presented, examining a patient group of adults intolerant to statins. The analysis identified factors associated with greater LDL cholesterol reduction when treated with bempedoid acid. These factors included female sex, higher baseline LDL cholesterol, and concurrent ezetimibe use. This outcome confirms previous observations and supports bempedoid acid's role as an alternative or adjunctive therapy to statins.

Esperion CEO Sheldon Koenig stated that the new analyses broaden the clinical evidence for bempedoid acid's effectiveness across diverse patient populations and support the use of the combination product NEXLIZET in helping patients achieve their LDL cholesterol goals and reduce cardiovascular risks. The company expressed pride in presenting data that supports bempedoid acid's use in children and informs ongoing Phase 3 studies.